Tracking Cathie Wood: Loading Up on Gene Editing and Precision Medicine, Trimming Tempus AI and Synthetic Biology

U.S. equities closed lower across the board on Friday, September 4, with the S&P 500 slipping 0.38% to 7,718.60, the Nasdaq falling 0.29% to 26,506.99, and the Dow Jones shedding 0.51% to 53,414.25. Risk sentiment remained cautious throughout the session, with broad-based selling pressure weighing on growth assets.

Symbols

Against this softer backdrop, ARK Invest's trading activity on the day reflected a deliberate posture of rebalancing — concentrating new capital into precision medicine and gene editing while trimming exposure to AI-driven healthcare data and synthetic biology, suggesting a possible structural optimization of portfolio allocation.

Buy: Doubling Down on Genomic Innovation and Solana Ecosystem

$Intellia Therapeutics (NTLA.US)$ saw the largest buy of the day, with ARK adding 31,186 shares. As a pioneer in in vivo CRISPR gene editing, Intellia occupies a central position in ARK's long-term precision medicine thesis. Continued clinical progress in gene editing therapies may have reinforced ARK's conviction in the company's long-term valuation re-rating potential.

$Robinhood (HOOD.US)$ was increased by 28,589 shares. Robinhood continues to evolve into a full-stack financial platform, spanning crypto assets, retirement accounts, and wealth management. The growing network effects of its user ecosystem may be building a durable competitive moat, and ARK's purchase could reflect confidence in retail fintech's growth trajectory through the next liquidity cycle.

$Veracyte (VCYT.US)$ was increased by 22,144 shares. Veracyte specializes in genomics-driven cancer diagnostics, with differentiated products across thyroid and lung cancer indications. This addition may reflect ARK's view that precision diagnostics will see sustained penetration gains as healthcare systems increasingly prioritize cost-effective, evidence-based decision-making.

3iQ Solana Staking ETF (SOLQ.U.US) was increased by 3,392 shares. ARK's continued accumulation of this instrument suggests a desire to capture upside from Solana's expanding ecosystem in the high-performance blockchain space, while also benefiting from the compounding effect of staking yields.

Sell: Trimming AI Healthcare and Synthetic Biology to Reallocate Capital

$Tempus AI (TEM.US)$ was reduced by 20,180 shares. While Tempus AI's AI-powered precision medicine data platform aligns well with ARK's core themes, this trim may be related to position concentration management or a reallocation of capital toward earlier-stage gene editing names with what ARK may perceive as more compelling risk-reward profiles.

$Twist Bioscience (TWST.US)$ was reduced by 12,300 shares. Twist is a key infrastructure provider in synthetic biology, offering DNA synthesis services. The reduction could possibly reflect a broader sector rotation within the portfolio — shifting capital away from synthetic biology infrastructure toward gene therapy assets more directly positioned to benefit from near-term clinical catalysts.

Not sure what to buy? Let the concentrated portfolios of top investors be your guide. This page aggregates high-conviction ideas from the world's best.

123K Views